GOLDMAN SACHS GROUP INC - NABRIVA THERAPEUTICS PLC ownership

NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 49 filers reported holding NABRIVA THERAPEUTICS PLC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of NABRIVA THERAPEUTICS PLC
ValueSharesWeighting
Q3 2020$30,000
+233.3%
56,537
+334.9%
0.00%
Q2 2020$9,000
-87.0%
13,000
-89.1%
0.00%
Q1 2020$69,000
-78.9%
119,181
-11.0%
0.00%
Q1 2019$327,000
+890.9%
133,897
+493.0%
0.00%
Q4 2018$33,000
-82.6%
22,578
-67.9%
0.00%
Q3 2018$190,000
-39.1%
70,444
-21.3%
0.00%
Q2 2018$312,000
-18.1%
89,536
+18.1%
0.00%
Q1 2018$381,000
-40.2%
75,808
-28.8%
0.00%
Q4 2017$637,000106,4430.00%
Other shareholders
NABRIVA THERAPEUTICS PLC shareholders Q4 2018
NameSharesValueWeighting ↓
Vivo Capital, LLC 4,074,190$33,368,0006.74%
Novo Holdings A/S 2,903,800$23,782,0003.10%
PURA VIDA INVESTMENTS, LLC 425,000$3,481,0001.02%
ACUTA CAPITAL PARTNERS, LLC 400,000$3,276,0000.59%
Monashee Investment Management LLC 188,000$1,540,0000.58%
Orbimed Advisors 3,919,600$32,102,0000.31%
FT Options LLC 20,000$164,0000.25%
Rock Springs Capital Management LP 625,000$5,119,0000.24%
Rubric Capital Management LP 300,000$2,457,0000.22%
Ghost Tree Capital, LLC 120,000$983,0000.21%
View complete list of NABRIVA THERAPEUTICS PLC shareholders